China’s regulatory authorities have given the thumbs-up to Mitsubishi Tanabe Pharma’s amyotrophic lateral sclerosis (ALS) treatment edaravone, making it the sixth country to approve the drug, which is otherwise known as Radicut or Radicava. The National Medical Products Administration of…
To read the full story
Related Article
- Mitsubishi Tanabe ALS Drug Accepted for Review in China
April 16, 2019
BUSINESS
- Nipro’s Stemirac Clinches Full Approval in Japan
November 17, 2026
- Kyorin Bags Japan Rights to Acadia’s Rett Syndrome Drug
November 17, 2026
- Eisai, J&J, Takeda among Firms Rolling Out Newly Listed Medicines in Japan
November 16, 2026
- Fuji Poised to Hit 10 Billion Yen Biosimilar Sales Mark, Led by Eylea Follow-On
November 16, 2026
- Seikagaku Sees Over a Year Before US Refiling of Herniated Disk Drug
November 16, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





